BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9489976)

  • 61. Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris.
    Rüegg PC; Nelson DJ
    Am J Med; 1989 Apr; 86(4A):70-4. PubMed ID: 2565689
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
    Mitrovic V; Oehm E; Thormann J; Pitschner H; Hamm C
    Herz; 2000 Mar; 25(2):130-42. PubMed ID: 10829253
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
    Rogers R; Prpic R
    Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris.
    Shlyakhto EV; Almazov VV; Nifontov EM; Vakhrameyeva IV; Rudomanov OG; Zakharov DV; Kazarin VV; Vakhrameyeva NV
    Am J Cardiovasc Drugs; 2002; 2(2):119-24. PubMed ID: 14727987
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
    Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
    Leon MB; Rosing DR; Bonow RO; Epstein SE
    Am J Cardiol; 1985 Jan; 55(3):69B-80B. PubMed ID: 2857518
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mibefradil release expands calcium-channel-blocker choices.
    Am J Health Syst Pharm; 1997 Sep; 54(18):2033. PubMed ID: 9377200
    [No Abstract]   [Full Text] [Related]  

  • 70. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
    Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O
    Cardiologia; 1996 Jul; 41(7):635-43. PubMed ID: 8831181
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
    Oparil S
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart.
    Rosenquist M; Brembilla-Perrot B; Meinertz T; Neugebauer A; Crijns HJ; Smeets JL; van der Vring JA; Fromer M; Kobrin I
    Eur J Clin Pharmacol; 1997; 52(1):7-12. PubMed ID: 9143860
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Mibefradil: a new class calcium inhibitor].
    Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
    [No Abstract]   [Full Text] [Related]  

  • 74. [Mibefradil opens up a new class of calcium antagonists. Glasgow, 23 June 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(39 Suppl):1-4. PubMed ID: 9212757
    [No Abstract]   [Full Text] [Related]  

  • 75. Hemolysis on intravenous administration of a new calcium antagonist.
    Kleinbloesem CH; Siepmann M; Kirch W
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):855-8. PubMed ID: 7564328
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 77. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
    Thadani U; Ezekowitz M; Fenney L; Chiang YK
    Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers.
    Uusitalo A
    Drugs; 1987; 33 Suppl 4():111-7. PubMed ID: 2887418
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis.
    Klein WW; Jackson G; Tavazzi L
    Coron Artery Dis; 2002 Dec; 13(8):427-36. PubMed ID: 12544718
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects.
    Strauss WE; Parisi AF
    Ann Intern Med; 1988 Oct; 109(7):570-81. PubMed ID: 2901816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.